Phio Pharmaceuticals’ (PHIO) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Phio Pharmaceuticals (NASDAQ:PHIO) in a report issued on Wednesday,Benzinga reports. They currently have a $4.00 price objective on the stock. HC Wainwright also issued estimates for Phio Pharmaceuticals’ Q4 2024 earnings at ($1.23) EPS, FY2024 earnings at ($8.54) EPS and FY2025 earnings at $3.76 EPS.

Phio Pharmaceuticals Trading Down 2.9 %

Shares of NASDAQ PHIO opened at $1.67 on Wednesday. The company has a market cap of $11.51 million, a price-to-earnings ratio of -0.15 and a beta of 1.53. Phio Pharmaceuticals has a 12 month low of $1.53 and a 12 month high of $10.35. The stock has a 50-day moving average price of $2.24 and a two-hundred day moving average price of $2.67.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Phio Pharmaceuticals stock. Virtu Financial LLC purchased a new position in shares of Phio Pharmaceuticals Corp. (NASDAQ:PHIO) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 40,910 shares of the company’s stock, valued at approximately $74,000. Virtu Financial LLC owned about 0.59% of Phio Pharmaceuticals at the end of the most recent quarter. Institutional investors own 57.31% of the company’s stock.

Phio Pharmaceuticals Company Profile

Phio Pharmaceuticals Corp. engages in the development of immuno-oncology therapeutics in the United States. The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells’ ability to kill cancer cells; and PH-762 treated double positive tumor infiltrating lymphocytes, which is in Phase 1 clinical trials to treat advanced melanoma and other advanced solid tumors.